Pressure Bio develops, markets and sells proprietary lab instruments and consumables to the $6 billion life science sample prep market.
Their patented PCT platform has been installed in over 250 PCT systems in 160 sites worldwide.
The company’s PCT product line has grown rapidly over the past year and as a result, product revenue has jumped 8.3% and total revenue increased 34% last year.
Although it’s in the early stages of commercialization the company’s PCT platform holds competitive advantages over incumbent technologies in many important aspects related to sample preparation.
A report from Zach’s Small Cap Research Analyst, Grant Zeng, stated that PBIO’s shares are deeply undervalued and based on current fundamentals gave a conservative price target of $2.50 per share.
Pressure Bio was also recently featured in an article on SECFilings.com, “How to Invest in the Cancer Moonshot” which you can read here: http://bit.ly/2f5JbDA
Pressure BioSciences, Inc. (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company’s products are based on the unique properties of both constant and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. The Company’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
PBIO’s Pressure Cycling Technology platform (PCT) is patented and uses alternate cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant and microbial sources. The Company has sold 300 instrument systems worldwide to leading academic, government, biotech and pharma laboratories. Additionally, there have been over 100 journal articles and peer reviewed publications on the advantages of PCT technology. Following a recent $6.3 million capital raise, a recent co-marketing deal with SCIEX (leader in mass spectrometry (MS)), and an expansion of the Company’s sales and marketing team, sales should begin to show strong increases going forward.
PBIO CEO Richard T. Schumacher is a serial entrepreneur who has had substantial success in growing and operating Biotech and Pharma businesses in the past; as President and Co-founder of Panacos Pharma, he helped to significantly improve the Company from a struggling start-up to a $700 million market cap in five years. Relative to sales potential, if PBIO can capture only 25% of the market opportunity in MS, it could lead to $75 million in device sales and $36 million in annual, recurring revenue. Additional long-term opportunities for PCT also exist.
Forward Looking Statements
This CEOLIVE.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.
Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.
CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information is provided for informational or entertainment purposes only. CEOLIVE is not a registered broker-dealer or a registered investment advisor.